Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

  • May 5, 2026

Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH).

Leave A Comment

Fields (*) Mark are Required